AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares start trading directly on the New York Stock Exchange today, establishing a harmonised global listing along with London and Stockholm.
Up to now, US investors could buy the drugmaker's equity via American Depositary Receipts (ADRs), which were listed on the Nasdaq, with each two representing one of the company’s ordinary shares.
It said the move to terminate the ADRs and switch to direct listings on the NYSE under a unified structure with the London Stock Exchange and Nasdaq Stockholm will provide "broader access" to US investors. Listings in the UK and Sweden remain unaffected.
Chair Michel Demaré said it "marks the start of an exciting new period for AstraZeneca, one which we believe gives broader access to the largest capital market in the world".
He said the harmonised listing across New York, London and Stockholm "reflects strong shareholder support for our growth strategy and positions AstraZeneca to deliver more innovative medicines to more patients around the world".
The prior Nasdaq listing of AstraZeneca’s ADRs and its US dollar bonds ended on 30 January 2026, with those bonds now trading on the NYSE too.
Lynn Martin, president of NYSE Group, said: “Today we are proud to welcome AstraZeneca to the NYSE, where it joins a community of groundbreakers and industry leaders. Through its listing on the world's largest and most liquid capital market, the company is well-positioned to expand its global investor base and accelerate its commitment to delivering innovation to patients and the wider biopharmaceutical industry.”
AZ also announced that its Imfinzi-based perioperative regimen has been recommended for approval in the European Union for patients with early-stage and locally advanced gastric and gastroesophageal junction cancers.
The EU's CHMP has recommended approval of Imfinzi (durvalumab) plus FLOT chemotherapy as a perioperative treatment, meaning the treatment would be given before, during and after surgery.
The recommendation follows results from the Phase III Matterhorn trial, which showed a 29% reduction in disease progression, recurrence or death and a 22% reduction in mortality versus chemotherapy alone.
“This durvalumab-based perioperative regimen is the first immunotherapy approach to significantly extend survival in this setting,” said Josep Tabernero, trial lead.
If approved, Imfinzi would be the first immunotherapy-based perioperative option for this indication in the EU. Approval decisions are pending in other regions.